SciSparc Enters Endoscopic Market with Major Strategic Patent Acquisition to Disrupt the Multi-Billion Dollar GERD Device Sector

On January 13, 2026, SciSparc Ltd. (Nasdaq: SPRC) announced that it had reached a definitive agreement to acquire a comprehensive treasury of intellectual property from Xylo Technologies Ltd., and this SciSparc patent acquisition deal marked a major change in the medical technology sector. Investor excitement over this bold entry into the endoscopic device sector has been swift, and SciSparc’s stock price has skyrocketed in reaction. The company is shifting away from its usual concentration on medicinal cannabis medications and toward a diverse future in advanced surgical imaging and minimally invasive diagnostics by acquiring valuable assets like the MUSE system.

The Strategic Significance of SciSparc Patent Acquisition Deal in Medical Imaging

The acquisition of the MUSE system, an advanced, single-use endoscopic instrument made especially for transoral fundoplication, is at the center of this transaction. For those with Gastroesophageal Reflux Disease (GERD), a condition that affects millions of people worldwide, this technique provides a minimally invasive alternative. SciSparc may now enter a market that was estimated to be worth $2.5 billion in 2024 and is expected to grow to over $3 billion by 2030, thanks to this patent purchase. The “ready-to-market” aspect of this technology is what attracts investors. The MUSE system is a proven technology platform that enables SciSparc to earn income significantly more quickly than its pharmaceutical pipeline may permit, in contrast to long-term pharmacological trials that can take a decade to yield results.

Read Also: Nokia and Hisense Settle All Litigation Through Strategic Video Patent Deal

Navigating the Complexities of Global Patent Filing and Portfolio Development

It takes more than one acquisition to stay ahead of the competition in the medical device industry, it also takes devotion to ongoing innovation and diligent patent filing. SciSparc has said explicitly that it plans to protect and grow the technology it is gaining from Xylo. The business creates a “patent wall” that keeps rivals from invading its space by recording each software update and technical advancement. For a microcap firm hoping to become a leader in surgical cameras and visualization equipment, this continuous cycle of development and legal protection is essential. Effective filing techniques guarantee that the company’s market dominance is unaffected as technology advances.

Unlocking Value Through Proactive Patent Monetization and Distribution Strategies

The enormous potential for patent monetization is a key factor in the recent spike in SciSparc’s stock price. SciSparc is using a successful business strategy that was previously implemented by Xylo, which in 2019 obtained a $3 million upfront payment through a licensing arrangement in Greater China. By pursuing exclusive alliances and license agreements throughout North America, Europe, and Latin America, SciSparc intends to duplicate this accomplishment. The company can generate quick cash flow through royalties and licensing fees by using its intellectual property as a financial asset. In addition to providing funding for the company’s other drug research initiatives, this strategy offers a more stable financial base, which is crucial as the business strives to satisfy Nasdaq’s standards for stockholder equity.

How the Endoscopic Patent Acquisition Impacts Investor Sentiment and Shareholder Equity

The market’s rapid reaction to the final deal caused shares to soar as high as 37% in early trading sessions. The increase in “bullish” sentiment among institutional and individual investors who view the acquisition as a de-risking event is reflected in this rise. According to the SciSparc patent acquisition deal SciSparc patent acquisition deal
agreement, which is expected to be completed by March 8, 2026, SciSparc will give Xylo ordinary shares, or 19.99% of its total share capital. This flood of tangible, high-value intellectual property serves as a significant stabilizer for a company that previously encountered issues with its Nasdaq minimum equity requirements. It turns the company from a risky pharmaceutical venture into a med-tech competitor with plenty of assets.

Future Outlook for SciSparc and the Global Demand for Minimally Invasive Tools

SciSparc’s long-term prospects are now linked to the expanding global need for effective, patient-friendly surgical solutions. The demand for single-use devices like the MUSE system is anticipated to increase at a stable compound annual growth rate as medical professionals switch from open surgeries to endoscopic treatments. SciSparc is now situated at the center of biotechnology and cutting-edge medical devices through its majority-owned subsidiary, NeuroThera Labs Inc. SciSparc is developing a complex business strategy that will withstand market volatility and provide steady value to its shareholders by maintaining its emphasis on patent filing and aggressive patent monetization.